Edition:
India

ANI Pharmaceuticals Inc (ANIP.OQ)

ANIP.OQ on NASDAQ Stock Exchange Global Market

70.49USD
20 Jul 2018
Change (% chg)

$-0.07 (-0.10%)
Prev Close
$70.56
Open
$70.51
Day's High
$71.08
Day's Low
$70.29
Volume
30,133
Avg. Vol
28,817
52-wk High
$74.63
52-wk Low
$42.26

Chart for

About

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.... (more)

Overall

Beta: 2.84
Market Cap(Mil.): $624.28
Shares Outstanding(Mil.): 11.64
Dividend: --
Yield (%): --

Financials

BRIEF-ANI Pharmaceuticals Reports Q1 GAAP Earnings Per Share $0.19

* ANI PHARMACEUTICALS REPORTS FIRST QUARTER 2018 RESULTS AND REAFFIRMS GUIDANCE

08 May 2018

BRIEF-Ani Pharmaceuticals To Acquire Generic Products And Assets From Amneal/Impax

* ANI PHARMACEUTICALS SIGNS DEFINITIVE AGREEMENTS TO ACQUIRE GENERIC PRODUCTS AND ASSETS FROM AMNEAL/IMPAX

28 Apr 2018

BRIEF-ANI Pharmaceuticals Announces Approval Of Morphine Sulfate Oral Solution

* ANI PHARMACEUTICALS ANNOUNCES APPROVAL OF MORPHINE SULFATE ORAL SOLUTION

18 Apr 2018

BRIEF-ANI Acquires 23 ANDAs From IDT Australia

April 4 ANI Pharmaceuticals Inc - Deal For $2.6 Mln And A Limited Single :

04 Apr 2018

BRIEF-IDT Australia To Divest Selection Of Generic Product Portfolio To Ani Pharmaceuticals

* TO DIVEST A SELECTION OF ITS GENERIC PRODUCT PORTFOLIO TO ANI PHARMACEUTICALS INC

04 Apr 2018

BRIEF-ANI Pharmaceuticals Q4 Adjusted Non-GAAP Earnings Per Share $1.08

* ANI PHARMACEUTICALS REPORTS RECORD FULL YEAR RESULTS, REPORTS FOURTH QUARTER 2017 RESULTS, AND PROVIDES 2018 GUIDANCE

27 Feb 2018

Earnings vs. Estimates